mGlu5positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome
Authors:
Open Access
- 2 March 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 25 (10) , 1990-2004
Abstract
Rett syndrome (RS) is a neurodevelopmental disorder that shares many symptomatic and pathological commonalities with idiopathic autism. Alterations in protein synthesis-dependent synaptic plasticity (PSDSP) are a hallmark of a number of syndromic forms of autism; in the present work, we explore the consequences of disruption and rescue of PSDSP in a mouse model of RS. We report that expression of a key regulator of synaptic protein synthesis, the metabotropic glutamate receptor 5 (mGlu5) protein, is significantly reduced in both the brains of RS model mice and in the motor cortex of human RS autopsy samples. Furthermore, we demonstrate that reduced mGlu5 expression correlates with attenuated DHPG-induced long-term depression in the hippocampus of RS model mice, and that administration of a novel mGlu5 positive allosteric modulator (PAM), termed VU0462807, can rescue synaptic plasticity defects. Additionally, treatment of Mecp2-deficient mice with VU0462807 improves motor performance (open-field behavior and gait dynamics), corrects repetitive clasping behavior, as well as normalizes cued fear-conditioning defects. Importantly, due to the rationale drug discovery approach used in its development, our novel mGlu5 PAM improves RS phenotypes and synaptic plasticity defects without evoking the overt adverse effects commonly associated with potentiation of mGlu5 signaling (i.e. seizures), or affecting cardiorespiratory defects in RS model mice. These findings provide strong support for the continued development of mGlu5 PAMs as potential therapeutic agents for use in RS, and, more broadly, for utility in idiopathic autism.Keywords
Funding Information
- Autism Speaks
- National Institutes of Health (R21 MH102548, R01 NS031373)
- RettSyndrome.org
- RettSyndrome.org
- Vanderbilt University
- Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation
This publication has 71 references indexed in Scilit:
- The Metabotropic Glutamate Receptor 4-Positive Allosteric Modulator VU0364770 Produces Efficacy Alone and in Combination with l-DOPA or an Adenosine 2A Antagonist in Preclinical Rodent Models of Parkinson’s DiseaseThe Journal of Pharmacology and Experimental Therapeutics, 2012
- Functional Impact of Allosteric Agonist Activity of Selective Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 in Regulating Central Nervous System FunctionMolecular Pharmacology, 2012
- Mutations causing syndromic autism define an axis of synaptic pathophysiologyNature, 2011
- Characterization of a commonly used mouse model of SMA reveals increased seizure susceptibility and heightened fear response in FVB/N miceNeurobiology of Disease, 2011
- Discovery of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Reveals Chemical and Functional Diversity and In Vivo Activity in Rat Behavioral Models of Anxiolytic and Antipsychotic ActivityMolecular Pharmacology, 2010
- Correction of respiratory disorders in a mouse model of Rett syndromeProceedings of the National Academy of Sciences, 2010
- Discovery of a Novel Chemical Class of mGlu5 Allosteric Ligands with Distinct Modes of PharmacologyACS Chemical Neuroscience, 2010
- mGluR5 Positive Allosteric Modulators Facilitate both Hippocampal LTP and LTD and Enhance Spatial LearningNeuropsychopharmacology, 2009
- Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant miceProceedings of the National Academy of Sciences, 2009
- The mGluR theory of fragile X mental retardationTrends in Neurosciences, 2004